138 related articles for article (PubMed ID: 23248552)
1. Long-term management of orbital and systemic reactive lymphoid hyperplasia with rituximab.
Chen A; Hwang TN; Phan LT; McCulley TJ; Yoon MK
Middle East Afr J Ophthalmol; 2012 Oct; 19(4):432-5. PubMed ID: 23248552
[TBL] [Abstract][Full Text] [Related]
2. Treatment of benign lymphoid hyperplasia of the orbit with rituximab.
Ho HH; Savar A; Samaniego F; Manning J; Kasyan A; Pro B; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2010; 26(1):11-3. PubMed ID: 20090476
[TBL] [Abstract][Full Text] [Related]
3. Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab.
Witzig TE; Inwards DJ; Habermann TM; Dogan A; Kurtin PJ; Gross JB; Ananthamurthy A; Ristow KM; Garity JA
Mayo Clin Proc; 2007 Jun; 82(6):692-9. PubMed ID: 17550749
[TBL] [Abstract][Full Text] [Related]
4. Novel therapeutic option for orbital atypical lymphoid hyperplasia.
Talaulikar D; Tridgell D; Leong D; Dahlstrom JE; Cherian M; Prosser I; Sunderland K
Clin Exp Ophthalmol; 2010 Dec; 38(9):892-4. PubMed ID: 20662847
[TBL] [Abstract][Full Text] [Related]
5. Treatment of cutaneous lymphoid hyperplasia with the monoclonal anti-CD20 antibody rituximab.
Martin SJ; Duvic M
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):286-8. PubMed ID: 21658657
[TBL] [Abstract][Full Text] [Related]
6. Treatment of orbital inflammation with rituximab in Wegener's granulomatosis.
Baslund B; Wiencke AK; Rasmussen N; Faurschou M; Toft PB
Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S7-10. PubMed ID: 22272561
[TBL] [Abstract][Full Text] [Related]
7. Adult orbital xanthogranuloma successfully treated with rituximab.
Satchi K; McNab AA; Godfrey T; Prince HM
Ophthalmology; 2014 Aug; 121(8):1664-5.e1-3. PubMed ID: 24811966
[No Abstract] [Full Text] [Related]
8. Intraorbital corticosteroid injection for orbital reactive lymphoid hyperplasia.
Andrew NH; Kearney D; Selva D
Eye (Lond); 2013 Apr; 27(4):561-3. PubMed ID: 23348726
[TBL] [Abstract][Full Text] [Related]
9. Clinical and histopathological findings of patients with orbital granulomatosis with polyangiitis cases refractory to rituximab.
Starr MR; Garrity JA; Tooley AA; Salomão DR
Can J Ophthalmol; 2019 Dec; 54(6):682-687. PubMed ID: 31836100
[TBL] [Abstract][Full Text] [Related]
10. Rituximab Monotherapy Is Effective in Treating Orbital Necrobiotic Xanthogranuloma.
Sagiv O; Thakar SD; Morrell G; Tetzlaff MT; Esmaeli B
Ophthalmic Plast Reconstr Surg; 2018; 34(1):e24-e27. PubMed ID: 28863117
[TBL] [Abstract][Full Text] [Related]
11. [Reactive lymphoid hyperplasia of the orbit with intracranial extension].
El Khiyat I; Alouan A; Mahdi Y; Kharmoum J; Cherkaoui O; Tachfouti S; Amazouzi A; Daoudi R; Maher M; Cherradi N
J Fr Ophtalmol; 2015 Nov; 38(9):e211-3. PubMed ID: 26321651
[No Abstract] [Full Text] [Related]
12. Enlargement of the infraorbital nerve: an important sign associated with orbital reactive lymphoid hyperplasia or immunoglobulin g4-related disease.
Hardy TG; McNab AA; Rose GE
Ophthalmology; 2014 Jun; 121(6):1297-303. PubMed ID: 24613826
[TBL] [Abstract][Full Text] [Related]
13. Orbital B-lymphocyte depletion in a treatment failure of rituximab for thyroid eye disease.
Gess AJ; Silkiss RZ
Ophthalmic Plast Reconstr Surg; 2014; 30(1):e11-3. PubMed ID: 23531951
[TBL] [Abstract][Full Text] [Related]
14. Rituximab in IgG4-related inflammatory disease of the orbit and ocular adnexae.
Lindfield D
Eye (Lond); 2012 Oct; 26(10):1386. PubMed ID: 22814806
[No Abstract] [Full Text] [Related]
15. Refractory Wegener's granulomatosis: effect of rituximab on granulomatous bilateral orbital involvement.
Avshovich N; Boulman N; Slobodin G; Zeina AR; Rosner I; Rozenbaum M
Isr Med Assoc J; 2009 Sep; 11(9):566-8. PubMed ID: 19960854
[No Abstract] [Full Text] [Related]
16. Diagnostic Challenges and Treatment Options for Cutaneous T Cell Pseudolymphoma: A Case Study with Rituximab Treatment.
Balode D; Beļajeva L; Ruesseler V; Quaas A; Lejniece S
Am J Case Rep; 2020 Jan; 21():e919616. PubMed ID: 31919337
[TBL] [Abstract][Full Text] [Related]
17. Perineural involvement of the frontal nerve by benign lymphoid hyperplasia.
Prabhakaran VC; Crompton J; Singhall N; Madge SN; Selva D
Clin Exp Ophthalmol; 2008 Jul; 36(5):481-3. PubMed ID: 18925918
[No Abstract] [Full Text] [Related]
18. Topical steroids eye drops in conjunctival reactive lymphoid hyperplasia: Case report.
Moraes BRM; Nascimento MVDD; Neto EDDS; Santo RM
Medicine (Baltimore); 2017 Nov; 96(47):e8656. PubMed ID: 29381940
[TBL] [Abstract][Full Text] [Related]
19. Successful "medical" orbital decompression with adjunctive rituximab for severe visual loss in IgG4-related orbital inflammatory disease with orbital myositis.
Chen TS; Figueira E; Lau OC; McKelvie PA; Smee RI; Dawes LC; Agar A; Wilcsek G; Francis IC
Ophthalmic Plast Reconstr Surg; 2014; 30(5):e122-5. PubMed ID: 24481505
[TBL] [Abstract][Full Text] [Related]
20. Rituximab therapy for refractory idiopathic scleritis.
Bogdanic-Werner K; Fernandez-Sanz G; Alejandre Alba N; Ferrer Soldevila P; Romero-Bueno FI; Sanchez-Pernaute O
Ocul Immunol Inflamm; 2013 Aug; 21(4):329-32. PubMed ID: 23662782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
